{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:17:59Z","timestamp":1791958679240,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jsat.2020.108165","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T11:11:26Z","timestamp":1602241886000},"page":"108165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada"],"prefix":"10.1016","volume":"121","author":[{"given":"Dennis C.","family":"Wendt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Marsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Lizzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Mushquash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla L.","family":"Venner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Swansburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Sorlagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristapore","family":"Manoukian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payton","family":"Bernett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Radin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jsat.2020.108165_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.7326\/M20-1141","article-title":"An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19","volume":"173","author":"Alexander","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2020.108165_bb0010","author":"APM Research Lab"},{"issue":"1","key":"10.1016\/j.jsat.2020.108165_bb0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7326\/M20-1210","article-title":"When epidemics collide: Coronavirus disease 2019 (COVID-19) and the opioid crisis","volume":"173","author":"Becker","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2020.108165_bb0025","author":"Bellrichard"},{"issue":"6","key":"10.1016\/j.jsat.2020.108165_bb0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","article-title":"Evidence synthesis\u2014The opioid crisis in Canada: A national perspective","volume":"38","author":"Belzak","year":"2018","journal-title":"Health Promotion and Chronic Disease Prevention in Canada"},{"issue":"4","key":"10.1016\/j.jsat.2020.108165_bb0035","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/02791072.2011.628913","article-title":"Historical trauma among Indigenous Peoples of the Americas: Concepts, research, and clinical considerations","volume":"43","author":"Brave Heart","year":"2011","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2020.108165_bb0040","author":"Bruneau"},{"key":"10.1016\/j.jsat.2020.108165_bb0045","series-title":"Wide-ranging online data for epidemiologic research (WONDER)","author":"Centers for Disease Control and Prevention","year":"2016"},{"key":"10.1016\/j.jsat.2020.108165_bb0050","doi-asserted-by":"crossref","first-page":"112384","DOI":"10.1016\/j.socscimed.2019.112384","article-title":"The intersectional risk environment of people who use drugs","volume":"234","author":"Collins","year":"2019","journal-title":"Social Science and Medicine"},{"issue":"6","key":"10.1016\/j.jsat.2020.108165_bb0055","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.17269\/CJPH.106.4979","article-title":"Racial discrimination, post-traumatic stress and prescription drug problems among Aboriginal Canadians","volume":"106","author":"Currie","year":"2015","journal-title":"Canadian Journal of Public Health"},{"issue":"174","key":"10.1016\/j.jsat.2020.108165_bb0060","article-title":"Why cultural safety rather than cultural competency is required to achieve health equity: A literature review and recommended definition","volume":"18","author":"Curtis","year":"2019","journal-title":"International Journal for Equity in Health"},{"issue":"1","key":"10.1016\/j.jsat.2020.108165_bb0065","first-page":"3019","article-title":"Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians","volume":"15","author":"DeFlavio","year":"2015","journal-title":"Rural and Remote Health"},{"issue":"2","key":"10.1016\/j.jsat.2020.108165_bb0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.17269\/s41997-018-0055-4","article-title":"Community strengths in addressing opioid use in Northeastern Ontario","volume":"109","author":"Dorman","year":"2018","journal-title":"Canadian Journal of Public Health"},{"issue":"2","key":"10.1016\/j.jsat.2020.108165_bb0075","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1176\/appi.ps.201300235","article-title":"Medication-assisted treatment with methadone: Assessing the evidence","volume":"65","author":"Fullerton","year":"2014","journal-title":"Psychiatric Services"},{"issue":"4","key":"10.1016\/j.jsat.2020.108165_bb0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jsat.2020.108165_bb0085","series-title":"Critical perspectives on addiction","first-page":"79","article-title":"Two tiers of biomedicalization: Methadone, buprenorphine, and the racial politics of addiction treatment","volume":"Vol. 14","author":"Hansen","year":"2012"},{"issue":"3","key":"10.1016\/j.jsat.2020.108165_bb0090","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City","volume":"40","author":"Hansen","year":"2013","journal-title":"The Journal of Behavioral Health Services & Research"},{"key":"10.1016\/j.jsat.2020.108165_bb0095","author":"Hedgpeth"},{"key":"10.1016\/j.jsat.2020.108165_bb0100","author":"Indigenous Services Canada"},{"issue":"2","key":"10.1016\/j.jsat.2020.108165_bb0105","first-page":"160","article-title":"Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: Evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program","volume":"61","author":"Kanate","year":"2015","journal-title":"Canadian Family Physician"},{"key":"10.1016\/j.jsat.2020.108165_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2020.1624","article-title":"Comparison of driving times to opioid treatment programs and pharmacies in the US","author":"Kleinman","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2020.108165_bb0115","author":"Lakhani"},{"key":"10.1016\/j.jsat.2020.108165_bb0120","author":"Macyshon"},{"key":"10.1016\/j.jsat.2020.108165_bb0125","author":"Maher"},{"issue":"2","key":"10.1016\/j.jsat.2020.108165_bb0130","first-page":"137","article-title":"Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study","volume":"63","author":"Mamakwa","year":"2017","journal-title":"Canadian Family Physician"},{"key":"10.1016\/j.jsat.2020.108165_bb0135","author":"Priest"},{"key":"10.1016\/j.jsat.2020.108165_bb0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","article-title":"Comparing Canadian and United States opioid agonist therapy policies","volume":"74","author":"Priest","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"11","key":"10.1016\/j.jsat.2020.108165_bb0145","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1176\/appi.ps.201600397","article-title":"National overview of medication-assisted treatment for American Indians and Alaska Natives with substance use disorders","volume":"68","author":"Rieckmann","year":"2017","journal-title":"Psychiatric Services"},{"issue":"1","key":"10.1016\/j.jsat.2020.108165_bb0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1747-597X-9-34","article-title":"Cultural interventions to treat addictions in Indigenous populations: Findings from a scoping study","volume":"9","author":"Rowan","year":"2014","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.jsat.2020.108165_bb0155","author":"Silverman"},{"key":"10.1016\/j.jsat.2020.108165_bb0160","series-title":"Colonialism of the curve: Indigenous communities and bad Covid data (policy brief issue 63)","author":"Skye","year":"2020"},{"issue":"2","key":"10.1016\/j.jsat.2020.108165_bb0165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: Assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.jsat.2020.108165_bb0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.addbeh.2018.05.017","article-title":"Future directions for medication assisted treatment for opioid use disorder with American Indian\/Alaska Natives","volume":"86","author":"Venner","year":"2018","journal-title":"Addictive Behaviors"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220304220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220304220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:53:08Z","timestamp":1760039588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547220304220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":33,"alternative-id":["S0740547220304220"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108165","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108165"}}